Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.85 USD | -3.19% | +2.97% | +73.84% |
01/05 | Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 | CI |
12/04 | Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.84% | 25.94M | |
+2.93% | 108B | |
+8.82% | 105B | |
+0.82% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B |
- Stock Market
- Equities
- LPCN Stock
- News Lipocine Inc.
- Lipocine's Partner Company Secures US FDA Approval for Testosterone Replacement Therapy